Alnylam Pharmaceuticals - ALNY Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $216.19
  • Forecasted Upside: 40.51%
  • Number of Analysts: 17
  • Breakdown:
  • 0 Sell Ratings
  • 7 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
$153.86
▼ -3.44 (-2.19%)

This chart shows the closing price for ALNY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Alnylam Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALNY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALNY

Analyst Price Target is $216.19
▲ +40.51% Upside Potential
This price target is based on 17 analysts offering 12 month price targets for Alnylam Pharmaceuticals in the last 3 months. The average price target is $216.19, with a high forecast of $400.00 and a low forecast of $161.00. The average price target represents a 40.51% upside from the last price of $153.86.

This chart shows the closing price for ALNY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 17 contributing investment analysts is to moderate buy stock in Alnylam Pharmaceuticals. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 10 buy ratings
  • 7 hold ratings
  • 0 sell ratings
12/27/2022
  • 0 strong buy ratings
  • 10 buy ratings
  • 7 hold ratings
  • 0 sell ratings
3/27/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 7 hold ratings
  • 0 sell ratings
6/25/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 7 hold ratings
  • 0 sell ratings
9/23/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 7 hold ratings
  • 0 sell ratings
12/22/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 7 hold ratings
  • 0 sell ratings
3/21/2024
  • 0 strong buy ratings
  • 10 buy ratings
  • 7 hold ratings
  • 0 sell ratings
5/20/2024
  • 0 strong buy ratings
  • 10 buy ratings
  • 7 hold ratings
  • 0 sell ratings
6/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 7 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/7/2024HC WainwrightBoost TargetBuy ➝ Buy$395.00 ➝ $400.00Low
5/3/2024Chardan CapitalReiterated RatingBuy ➝ Buy$225.00 ➝ $225.00Low
5/2/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$200.00Low
4/8/2024William BlairReiterated RatingOutperformLow
3/27/2024BMO Capital MarketsReiterated RatingOutperform ➝ Outperform$234.00Low
3/5/2024HC WainwrightReiterated RatingBuy ➝ Buy$395.00Low
2/20/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$165.00Low
2/20/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$235.00Low
2/16/2024Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$171.00 ➝ $161.00Low
2/16/2024CitigroupLower TargetBuy ➝ Buy$237.00 ➝ $227.00Low
2/16/2024Chardan CapitalLower TargetBuy ➝ Buy$250.00 ➝ $225.00Low
2/16/2024The Goldman Sachs GroupDowngradeBuy ➝ Neutral$230.00 ➝ $173.00Low
2/15/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$200.00Low
2/15/2024Wolfe ResearchInitiated CoveragePeer PerformLow
2/14/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$235.00Low
2/13/2024Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$184.00 ➝ $176.00Low
2/12/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$165.00Low
2/1/2024JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$150.00 ➝ $170.00Low
1/18/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$165.00Low
1/8/2024William BlairReiterated RatingOutperformLow
12/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$395.00Low
12/14/2023Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$165.00Low
12/14/2023Piper SandlerBoost TargetOverweight ➝ Overweight$210.00 ➝ $217.00Low
12/8/2023Wells Fargo & CompanyInitiated CoverageEqual Weight$171.00Low
11/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$395.00Low
11/3/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$235.00 ➝ $230.00Low
11/3/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$175.00 ➝ $183.00Low
10/16/2023Cantor FitzgeraldLower TargetNeutral ➝ Neutral$190.00 ➝ $170.00Low
10/11/2023OppenheimerDowngradeOutperform ➝ Market PerformLow
10/11/2023Royal Bank of CanadaLower Target$270.00 ➝ $235.00Low
10/11/2023HC WainwrightLower TargetBuy ➝ Buy$405.00 ➝ $395.00Low
10/10/2023Sanford C. BernsteinLower Target$237.00 ➝ $218.00Low
10/10/2023Evercore ISILower Target$252.00 ➝ $210.00Low
10/10/2023BMO Capital MarketsLower TargetOutperform ➝ Outperform$250.00 ➝ $234.00Low
10/10/2023CitigroupLower TargetBuy ➝ Buy$266.00 ➝ $233.00Low
10/9/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$210.00 ➝ $175.00Low
10/9/2023Needham & Company LLCLower TargetBuy ➝ Buy$240.00 ➝ $200.00Low
10/6/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$270.00Low
9/28/2023Raymond JamesInitiated CoverageOutperform$208.00Low
9/18/2023HC WainwrightReiterated RatingBuy ➝ Buy$405.00Low
9/14/2023Stifel NicolausReiterated RatingBuy ➝ Buy$240.00Low
9/14/2023Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$190.00Low
9/12/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$240.00Low
9/12/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$270.00Low
8/28/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$270.00Low
8/18/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$270.00Low
8/16/2023Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$190.00Low
8/8/2023Chardan CapitalReiterated RatingBuy ➝ Buy$250.00Low
8/7/2023HC WainwrightReiterated RatingBuy ➝ Buy$405.00Low
8/4/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$210.00Low
8/4/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$270.00Low
8/4/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$240.00Low
8/4/2023CitigroupBoost TargetBuy ➝ Buy$265.00 ➝ $266.00Low
7/26/2023Sanford C. BernsteinLower Target$247.00 ➝ $233.00Low
7/25/2023William BlairReiterated RatingOutperformLow
7/25/2023Royal Bank of CanadaLower TargetOutperform$275.00 ➝ $270.00Low
7/25/2023HC WainwrightLower TargetBuy$415.00 ➝ $405.00Low
5/5/2023BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$200.00 ➝ $250.00Low
4/26/2023Sumitomo Mitsui Financial GroupInitiated CoverageNeutral$220.00Low
4/4/2023Morgan StanleyBoost TargetEqual Weight$205.00 ➝ $210.00Low
3/21/2023Sanford C. BernsteinInitiated CoverageOutperform$243.00Low
3/3/2023JPMorgan Chase & Co.Lower TargetNeutral$200.00 ➝ $196.00Low
3/3/2023HC WainwrightReiterated RatingBuy$415.00Low
2/24/2023Needham & Company LLCReiterated RatingBuy$240.00Low
2/24/2023Chardan CapitalReiterated RatingBuy$250.00Low
2/24/2023OppenheimerLower TargetOutperform$256.00 ➝ $249.00N/A
2/24/2023Morgan StanleyLower TargetEqual Weight$210.00 ➝ $205.00N/A
2/24/2023Canaccord Genuity GroupLower TargetBuy$310.00 ➝ $291.00Low
2/24/2023CitigroupLower TargetBuy$270.00 ➝ $265.00Low
2/21/2023EF Hutton Acquisition Co. IInitiated CoverageBuy$304.00Low
1/23/2023SVB LeerinkLower TargetMarket Perform$144.00 ➝ $143.00Low
1/18/2023Canaccord Genuity GroupInitiated CoverageBuy$310.00Low
12/16/2022Piper SandlerBoost TargetOverweight$226.00 ➝ $253.00Low
11/7/2022SVB LeerinkBoost TargetMarket Perform$142.00 ➝ $145.00Low
11/2/2022HC WainwrightLower TargetBuy$430.00 ➝ $415.00N/A
10/28/2022BarclaysLower TargetOverweight$240.00 ➝ $236.00Low
10/28/2022Morgan StanleyLower TargetEqual Weight$220.00 ➝ $210.00Low
10/28/2022The Goldman Sachs GroupBoost TargetBuy$239.00 ➝ $270.00Low
10/24/2022JPMorgan Chase & Co.Lower TargetNeutral$204.00 ➝ $200.00Low
10/13/2022Morgan StanleyLower TargetEqual Weight$222.00 ➝ $220.00Low
10/3/2022Jefferies Financial GroupBoost TargetBuy$218.00 ➝ $232.00Low
9/20/2022Royal Bank of CanadaBoost TargetOutperform$225.00 ➝ $250.00Low
9/9/2022Morgan StanleyReiterated RatingEqual Weight$225.00 ➝ $222.00Low
9/9/2022BMO Capital MarketsBoost TargetMarket Perform$192.00 ➝ $200.00Low
9/9/2022OppenheimerBoost TargetOutperform$170.00 ➝ $256.00Low
8/9/2022Evercore ISIBoost Target$252.00N/A
8/4/2022BMO Capital MarketsBoost TargetMarket Perform$166.00 ➝ $192.00Low
8/4/2022Morgan StanleyBoost TargetEqual Weight$159.00 ➝ $225.00N/A
8/4/2022Chardan CapitalBoost TargetBuy$200.00 ➝ $250.00Low
8/4/2022Needham & Company LLCBoost TargetBuy$205.00 ➝ $240.00Low
8/4/2022CitigroupBoost Target$206.00 ➝ $280.00Low
7/29/2022Morgan StanleyLower TargetEqual Weight$164.00 ➝ $159.00Low
7/29/2022CitigroupLower Target$211.00 ➝ $206.00Low
7/15/2022Morgan StanleyLower TargetEqual Weight$170.00 ➝ $164.00Low
7/12/2022Cantor FitzgeraldInitiated CoverageNeutral$175.00N/A
6/27/2022GuggenheimDowngradeBuy ➝ NeutralLow
6/16/2022Needham & Company LLCInitiated CoverageBuy$205.00High
6/15/2022SVB LeerinkBoost TargetMarket Perform$96.00 ➝ $98.00High
6/7/2022William BlairInitiated CoverageOutperformMedium
5/2/2022HC WainwrightBoost Target$400.00 ➝ $430.00Medium
4/29/2022CitigroupLower Target$223.00 ➝ $211.00High
4/25/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$210.00 ➝ $178.00Medium
4/12/2022HC WainwrightBoost TargetBuy$350.00 ➝ $400.00Medium
4/6/2022OppenheimerReiterated RatingOutperform$205.00Low
3/24/2022Stifel NicolausReiterated RatingBuy$215.00Low
2/28/2022CitigroupInitiated CoverageBuy$223.00High
2/23/2022Morgan StanleyLower TargetOverweight$215.00 ➝ $210.00Low
2/11/2022Chardan CapitalReiterated RatingBuy$200.00Medium
2/11/2022SVB LeerinkLower TargetMarket Perform$109.00 ➝ $103.00Medium
2/3/2022GuggenheimUpgradeNeutral ➝ Buy$170.00Low
1/28/2022SVB LeerinkBoost TargetMarket Perform$108.00 ➝ $109.00High
1/20/2022HC WainwrightBoost TargetBuy$250.00 ➝ $350.00High
1/18/2022Morgan StanleyLower TargetOverweight$226.00 ➝ $215.00High
1/3/2022Bank of AmericaReiterated RatingBuy ➝ Buy$211.00Medium
1/3/2022Piper SandlerUpgradeNeutral ➝ Overweight$181.00 ➝ $208.00Low
12/30/2021OppenheimerReiterated RatingOutperform$200.00Low
12/1/2021SVB LeerinkReiterated RatingHoldMedium
11/22/2021Needham & Company LLCBoost TargetBuy$180.00 ➝ $205.00High
11/22/2021The Goldman Sachs GroupUpgradeNeutral ➝ Buy$273.00High
11/22/2021Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$144.00 ➝ $225.00High
11/1/2021OppenheimerUpgradeMarket Perform ➝ Outperform$200.00Low
10/31/2021BMO Capital MarketsReiterated RatingHold ➝ NeutralMedium
10/29/2021Morgan StanleyLower TargetOverweight$242.00 ➝ $226.00High
10/29/2021Chardan CapitalBoost TargetBuy$190.00 ➝ $200.00High
10/29/2021Cantor FitzgeraldBoost TargetOverweight$202.00 ➝ $275.00Low
10/28/2021SVB LeerinkBoost TargetMarket Perform$104.00 ➝ $108.00High
10/18/2021SVB LeerinkReiterated RatingMarket PerformLow
10/12/2021Morgan StanleyBoost TargetOverweight$234.00 ➝ $242.00Low
10/4/2021UBS GroupUpgradeNeutral ➝ Buy$141.00 ➝ $215.00Low
8/27/2021BMO Capital MarketsBoost TargetNeutral ➝ Market Perform$174.00 ➝ $196.00Medium
8/13/2021HC WainwrightBoost TargetBuy$235.00 ➝ $250.00High
8/4/2021Chardan CapitalReiterated RatingBuy$190.00Medium
8/4/2021Morgan StanleyBoost TargetOverweight$224.00 ➝ $234.00High
8/4/2021BarclaysBoost TargetOverweight$196.00 ➝ $216.00High
8/4/2021Piper SandlerDowngradeOverweight ➝ Neutral$45.00 ➝ $47.00High
7/16/2021Morgan StanleyBoost TargetOverweight$205.00 ➝ $224.00High
4/30/2021Morgan StanleyLower TargetOverweight$206.00 ➝ $205.00Low
4/20/2021Needham & Company LLCReiterated RatingBuyLow
3/1/2021GuggenheimReiterated RatingBuy ➝ Neutral$162.00Low
2/22/2021GuggenheimDowngradeBuy ➝ Neutral$162.00Medium
2/14/2021Royal Bank of CanadaReiterated RatingHoldLow
2/12/2021Needham & Company LLCBoost TargetBuy$160.00 ➝ $180.00Low
2/12/2021Morgan StanleyBoost TargetOverweight$203.00 ➝ $206.00Low
2/12/2021CitigroupDowngradeBuy ➝ Neutral$170.00 ➝ $175.00Low
2/12/2021BarclaysBoost TargetOverweight$162.00 ➝ $196.00Low
2/12/2021HC WainwrightBoost TargetBuy$225.00 ➝ $235.00Low
1/25/2021BMO Capital MarketsDowngradeOutperform ➝ Market Perform$185.00 ➝ $185.00High
1/13/2021CowenBoost TargetIn-Line ➝ Outperform$154.00 ➝ $197.00High
1/8/2021HC WainwrightReiterated RatingBuy$225.00High
12/21/2020Royal Bank of CanadaLower TargetSector Perform$150.00 ➝ $144.00Medium
12/17/2020Piper SandlerBoost TargetOverweight$169.00 ➝ $181.00Low
11/25/2020BMO Capital MarketsBoost Target$182.00 ➝ $183.00Low
11/25/2020Morgan StanleyBoost TargetOverweight$200.00 ➝ $203.00Low
11/24/2020SVB LeerinkBoost TargetMarket Perform$90.00 ➝ $91.00Low
11/6/2020Morgan StanleyBoost TargetOverweight$197.00 ➝ $200.00High
10/15/2020Bank of AmericaLower TargetBuy$160.00 ➝ $157.00Low
10/12/2020Chardan CapitalReiterated RatingBuyLow
9/30/2020OppenheimerReiterated RatingHold$156.00Medium
9/30/2020Berenberg BankInitiated CoverageHold$145.00Medium
9/8/2020CitigroupInitiated CoverageBuy$170.00 ➝ $170.00Low
8/24/2020HC WainwrightReiterated RatingBuyLow
8/11/2020OppenheimerDowngradeOutperform ➝ Market Perform$162.00 ➝ $156.00Low
8/7/2020Morgan StanleyLower TargetOverweight$199.00 ➝ $197.00Low
8/7/2020Chardan CapitalReiterated RatingBuyLow
8/7/2020SVB LeerinkBoost TargetMarket Perform$89.00 ➝ $90.00Low
7/20/2020BMO Capital MarketsBoost TargetOutperform$173.00 ➝ $196.00High
7/15/2020Morgan StanleyBoost TargetOverweight$162.00 ➝ $199.00Low
5/28/2020UBS GroupBoost TargetNeutral$111.00 ➝ $122.00Low
5/12/2020Royal Bank of CanadaInitiated CoverageSector Perform$150.00Medium
5/7/2020BMO Capital MarketsBoost TargetOutperform$145.00 ➝ $171.00Low
5/7/2020OppenheimerBoost TargetOutperform$140.00 ➝ $162.00High
5/7/2020Morgan StanleyBoost TargetOverweight$148.00 ➝ $162.00High
5/7/2020BarclaysBoost TargetOverweight$143.00 ➝ $156.00High
5/7/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$133.00 ➝ $137.00High
5/6/2020Needham & Company LLCBoost TargetBuy$135.00 ➝ $160.00High
4/24/2020Evercore ISIInitiated CoverageBuy$160.00Low
4/14/2020Needham & Company LLCReiterated RatingBuy$135.00High
4/14/2020Cantor FitzgeraldBoost Target$195.00 ➝ $202.00Low
4/14/2020Piper SandlerLower Target$147.00 ➝ $142.00Medium
4/14/2020Nomura SecuritiesLower TargetReduce$75.00 ➝ $74.00Medium
4/13/2020OppenheimerReiterated RatingBuy$140.00Medium
3/19/2020Berenberg BankInitiated CoverageBuy$200.00Low
3/5/2020CowenReiterated RatingBuyMedium
3/3/2020Piper SandlerReiterated RatingBuy$155.00N/A
2/11/2020Nomura SecuritiesBoost TargetReduce$62.00 ➝ $75.00Medium
2/9/2020CowenReiterated RatingBuy$154.00High
2/7/2020Evercore ISIInitiated CoverageBuy$145.00High
2/7/2020Morgan StanleyLower TargetOverweight$150.00 ➝ $148.00Medium
2/7/2020Chardan CapitalReiterated RatingBuyHigh
2/7/2020Needham & Company LLCReiterated RatingBuyHigh
12/19/2019Chardan CapitalBoost TargetBuy$150.00 ➝ $190.00Low
12/18/2019Nomura SecuritiesReiterated RatingSell$62.00Low
12/18/2019Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$159.00 ➝ $176.00Medium
12/17/2019Piper Sandler CompaniesBoost TargetOverweight$145.00 ➝ $155.00Medium
12/17/2019Morgan StanleyBoost TargetOverweight$141.00 ➝ $150.00High
11/27/2019Cantor FitzgeraldBoost Target$150.00 ➝ $159.00Low
11/21/2019BMO Capital MarketsBoost TargetOutperform$128.00 ➝ $138.00High
11/21/2019BarclaysBoost TargetOverweight$125.00 ➝ $131.00High
11/21/2019Needham & Company LLCInitiated CoverageBuy$135.00Low
11/21/2019Cantor FitzgeraldReiterated RatingBuy$150.00 ➝ $159.00Low
11/19/2019OppenheimerInitiated CoverageOutperform$128.00 ➝ $128.00High
11/18/2019CowenReiterated RatingBuy$120.00High
11/13/2019Bank of AmericaInitiated CoverageBuy$110.00Low
10/31/2019Needham & Company LLCReiterated RatingBuy$135.00Low
10/8/2019Nomura SecuritiesSet TargetSell$62.00Low
9/10/2019Piper Sandler CompaniesSet TargetBuy$145.00High
9/4/2019UBS GroupBoost TargetNeutral$95.00 ➝ $96.00Low
9/3/2019Stifel NicolausSet TargetBuy$116.00Low
9/3/2019Piper Sandler CompaniesBoost TargetOverweight$142.00 ➝ $145.00Medium
8/26/2019Piper Sandler CompaniesSet TargetBuy$142.00Low
8/7/2019BarclaysReiterated RatingBuy$125.00High
8/7/2019Morgan StanleyLower TargetOverweight$126.00 ➝ $124.00High
8/7/2019CowenLower TargetOutperform$147.00 ➝ $120.00High
(Data available from 6/19/2019 forward)

News Sentiment Rating

1.49 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 12 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/22/2023
  • 16 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/22/2023
  • 11 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
1/21/2024
  • 31 very positive mentions
  • 21 positive mentions
  • 9 negative mentions
  • 0 very negative mentions
2/20/2024
  • 21 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/21/2024
  • 13 very positive mentions
  • 14 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
4/20/2024
  • 17 very positive mentions
  • 22 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
5/20/2024
  • 20 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/19/2024

Current Sentiment

  • 20 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Alnylam Pharmaceuticals logo
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $153.86
Low: $152.30
High: $157.32

50 Day Range

MA: $150.01
Low: $143.31
High: $160.39

52 Week Range

Now: $153.86
Low: $141.98
High: $218.88

Volume

587,562 shs

Average Volume

600,422 shs

Market Capitalization

$19.46 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.3

Frequently Asked Questions

What sell-side analysts currently cover shares of Alnylam Pharmaceuticals?

The following Wall Street sell-side analysts have issued research reports on Alnylam Pharmaceuticals in the last year: BMO Capital Markets, Cantor Fitzgerald, Chardan Capital, Citigroup Inc., Evercore ISI, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Royal Bank of Canada, Sanford C. Bernstein, Stifel Nicolaus, StockNews.com, The Goldman Sachs Group, Inc., Wells Fargo & Company, William Blair, and Wolfe Research.
View the latest analyst ratings for ALNY.

What is the current price target for Alnylam Pharmaceuticals?

16 Wall Street analysts have set twelve-month price targets for Alnylam Pharmaceuticals in the last year. Their average twelve-month price target is $216.19, suggesting a possible upside of 40.5%. HC Wainwright has the highest price target set, predicting ALNY will reach $400.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $161.00 for Alnylam Pharmaceuticals in the next year.
View the latest price targets for ALNY.

What is the current consensus analyst rating for Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals currently has 7 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ALNY.

What other companies compete with Alnylam Pharmaceuticals?

How do I contact Alnylam Pharmaceuticals' investor relations team?

Alnylam Pharmaceuticals' physical mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The biopharmaceutical company's listed phone number is (617) 551-8200 and its investor relations email address is [email protected]. The official website for Alnylam Pharmaceuticals is www.alnylam.com. Learn More about contacing Alnylam Pharmaceuticals investor relations.